ArticleTranslational pediatrics2026
Association between multi-oil fat emulsion and bronchopulmonary dysplasia in preterm infants <32 weeks.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchopulmonary dysplasia (BPD) is a major respiratory morbidity in preterm infants and remains an important cause of adverse short- and long-term outcomes. Early postnatal nutrition may influence lung growth and injury repair, and intravenous lipid emulsions are a key component of parenteral nutrition in very preterm infants. Compared with conventional medium-chain/long-chain triglyceride fat emulsions (MCT/LCT), multi-oil fat emulsion (SMOF) contains fish oil and vitamin E, etc., and has a lower relative proportion of ω-6 fatty acids, and may theoretically attenuate inflammation and oxidative stress. However, current evidence regarding whether SMOF reduces the incidence of BPD remains inconsistent. This study aimed to evaluate the association between SMOF and BPD in preterm infants born at <32 weeks' gestation. Methods: A retrospective analysis included 171 preterm infants (<32 weeks) admitted to a tertiary neonatal intensive care unit, divided into SMOF (n=96) and MCT/LCT (n=75) groups. The outcome of respiratory system and other complications such as parenteral nutrition-related cholestasis (PNAC), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), late-onset of sepsis (LOS), brain injury and mortality were compared between the two groups. Results: Among the 171 preterm infants in the study, the mean gestational age was 29.51±1.55 weeks, with birth weight of 1,229.39±299.06 g. Multivariate analysis identified SMOF as an independent protective factor against BPD [odds ratio (OR) =0.317, 95% confidence interval (CI): 0.128-0.784]. No significant differences were observed in PNAC, ROP, NEC, sepsis, brain injury, or mortality between groups. Conclusions: We preliminarily conclude that SMOF is a potentially protective factor for BPD in preterm infants <32 weeks without increasing complications such as PNAC, ROP, NEC, sepsis, and brain injury. These findings may support its clinical utility in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.